Evaluation of Optimal Time of Methimazole Discontinuation Before Radio-iodine Therapy in Hyperthyroid Grave's Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01560299|
Recruitment Status : Completed
First Posted : March 22, 2012
Last Update Posted : March 22, 2012
Iodine therapy is the best treatment for graves disease.Most patients receive methimozale prior to radio-iodine treatment. This may decrease treatment response to iodine therapy.
Some physicians advice to discontinue methimazole 3 days before radioiodine therapy and others prefer longer off - methimazole period which bothers most patients. This study aimed to evaluate optimum time for methimazole discontinuation in graves disease.
|Condition or disease||Intervention/treatment||Phase|
|Graves Disease||Drug: Methimazole||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||150 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||None (Open Label)|
|Study Start Date :||February 2010|
|Actual Primary Completion Date :||January 2012|
|Actual Study Completion Date :||January 2012|
Active Comparator: group one
This group will be advised to discontinue methimazole 24-48 hour before iodine therapy
Methimazole was stopped 24-48 before radio-iodine therapy
Active Comparator: group two
methimazole stopped 48-72 hour before radioiodine therapy
methimazole discontinued 49-72 hours before radioiodine treatment
|Active Comparator: group three||
methimazole discontinued 73-168 hours before radio-iodine treatment
- thyroid function tests over one year after radioiodine therapy [ Time Frame: months 1 , 3 ,6,9,12 ]thyroid function test may change over one year . In order to consider the patients as cured ,thyroid function tests should reveal hypothyroidism or euthyroidism . In order to rule out temporary hypothyroidism the tests should be repeated after 6 months of radioiodine therapy.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01560299
|Iran, Islamic Republic of|
|Mashad University of Medical Sciences|
|Mashad, Khorasan Razavi, Iran, Islamic Republic of, 91766|
|Principal Investigator:||rasoul zakavi, associate professor||Mashhad University of Medical Sciences|